Finnish biopharmaceutical company Biotie Therapies (OMXH: BTH1V) got some much needed positive news with its Synosia Therapeutics acquired product candidates with adenosine A2a antagonist tozadenant (SYN115) meeting primary and numerous secondary endpoints in Parkinson’s disease in patients with Levodopa end of dose wearing off. The 420 patients study compared the off time vs. placebo in 420 patients suffering from advanced parkinson’s. Secondary endpoints included various validated rating scale as well as clinician and patient patient improvement evaluations.
CEO Timo Veromaa exxpressed hope that the study could be considered pivotal. The compound is licensed worldwide to UCB Pharma S.A (Euronext: UCB). The partners will assess following steps with UCB responsible for further development. Decision from the large multinational is expected early next year. More detailed results will be released at a medical conference and in scientific publications. Another important event is expected soon with a decision on European Marketing Approval for the lead drug candidate Selincro (nalmefene) expected soon.
No comments:
Post a Comment